RxDoctor Payments Data

Timothy Jayasundera

Cardiovascular Disease · New York, NYNPI 1811908205

Payments from drug & device makers

$87,195in general payments, 2019–2025

Across 286 payments — averaging $304.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$43K
  • Esperion Therapeutics, Inc.$39K
  • Amgen$3K
  • Boston Scientific$486
  • Bayer$187
  • Heartflow, Inc.$178
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$74,85086%
  • Travel & lodging$3,7444%
  • Food & beverage$8,57310%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,195 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$478,955
Medicare patients
302
Services billed
3,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol139$176,276
BrilintaTicagrelor117$130,174
EliquisApixaban68$92,552
JanuviaSitagliptin Phosphate74$88,742
XareltoRivaroxaban68$81,925
EntrestoSacubitril/Valsartan48$72,261
TrulicityDulaglutide12$33,173
JanumetSitagliptin Phos/Metformin Hcl29$33,018
TradjentaLinagliptin20$27,012
JardianceEmpagliflozin23$26,184
VascepaIcosapent Ethyl30$16,750
Janumet XrSitagliptin Phos/Metformin Hcl17$15,443
Olmesartan Medoxomil305$13,759
Praluent PenAlirocumab18$12,235
NexlizetBempedoic Acid/Ezetimibe11$11,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$43,218$306,450256 claims
MerckJanuvia, Janumet, Janumet Xr$86$137,203120 claims
Johnson & JohnsonXarelto$96$81,92568 claims
NovartisEntresto$125$72,26148 claims
Boehringer IngelheimTradjenta, Jardiance$38$53,19643 claims
Lilly USA, LLCTrulicity$63$33,17312 claims
Esperion Therapeutics, Inc.Nexlizet$38,768$11,58711 claims
Sanofi-aventis U.S. LLCMultaq$34$9,41912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →